Skip to content Skip to footer

Biocon Biologics Report the P-III Study Positive Results of Yesintek (Biosimilar, Stelara) 

Shots: 

  • Biocon Biologics revealed positive results from the P-III study demonstrating that Yesintek achieved equivalent efficacy, safety, immunogenicity, and PK vs reference product to treat mod. to sev. chronic plaque psoriasis (PsO) pts. (n=384, age= 18-80yrs.); data was presented at AAD 2025 
  • The primary efficacy endpoint, percentage change in PASI scores at Wk. 12 showed similar improvement, with a mean difference of 0.68%, within predefined equivalence margins of the US FDA & EMA. Switching from Stelara to YESINTEK at Wk. 16 maintained efficacy & safety through Wk. 52 
  •  Yesintek (mAb) targets interleukins IL-12 and IL-23, approved for the treatment of Crohn’s disease, Ulcerative Colitis, PsO and Psoriatic Arthritis 

Ref: Biocon Biologics| Image: Biocon Biologics| Press Release

Related News:- Biocon Biologics Launches Yesintek (Biosimilar, Stelara) in the US

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]